These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 20601872)

  • 1. Treatment options in heparin-induced thrombocytopenia.
    Hook KM; Abrams CS
    Curr Opin Hematol; 2010 Sep; 17(5):424-31. PubMed ID: 20601872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia.
    Dang CH; Durkalski VL; Nappi JM
    Pharmacotherapy; 2006 Apr; 26(4):461-8. PubMed ID: 16553503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of Fondaparinux Off-Label or Approved Anticoagulants for Management of Heparin-Induced Thrombocytopenia.
    Schindewolf M; Steindl J; Beyer-Westendorf J; Schellong S; Dohmen PM; Brachmann J; Madlener K; Pötzsch B; Klamroth R; Hankowitz J; Banik N; Eberle S; Müller MM; Kropff S; Lindhoff-Last E
    J Am Coll Cardiol; 2017 Nov; 70(21):2636-2648. PubMed ID: 29169470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct thrombin inhibition during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.
    Lewis BE; Hursting MJ
    Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):57-68. PubMed ID: 17187457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antithrombotic drugs for the treatment of heparin-induced thrombocytopenia.
    Jeske WP; Walenga JM
    Curr Opin Investig Drugs; 2002 Aug; 3(8):1171-80. PubMed ID: 12211410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bivalirudin.
    Warkentin TE; Greinacher A; Koster A
    Thromb Haemost; 2008 May; 99(5):830-9. PubMed ID: 18449412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bivalirudin for the treatment of patients with confirmed or suspected heparin-induced thrombocytopenia.
    Joseph L; Casanegra AI; Dhariwal M; Smith MA; Raju MG; Militello MA; Gomes MP; Gornik HL; Bartholomew JR
    J Thromb Haemost; 2014 Jul; 12(7):1044-53. PubMed ID: 24766902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heparin-induced thrombocytopenia: comparison between response to fondaparinux and lepirudin.
    Al-Rossaies A; Alkharfy KM; Al-Ayoubi F; Al-Momen A
    Int J Clin Pharm; 2011 Dec; 33(6):997-1001. PubMed ID: 22002684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Percutaneous interventions in patients with immune-mediated heparin-induced thrombocytopenia.
    Nikolsky E; Dangas GD
    Semin Thromb Hemost; 2004 Jun; 30(3):305-14. PubMed ID: 15282653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of heparin-induced thrombocytopenia: is there a role for bivalirudin?
    Seybert AL; Coons JC; Zerumsky K
    Pharmacotherapy; 2006 Feb; 26(2):229-41. PubMed ID: 16466327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heparin-induced thrombocytopenia: treatment options and special considerations.
    Dager WE; Dougherty JA; Nguyen PH; Militello MA; Smythe MA
    Pharmacotherapy; 2007 Apr; 27(4):564-87. PubMed ID: 17381384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fondaparinux as a treatment option for heparin-induced thrombocytopenia.
    Papadopoulos S; Flynn JD; Lewis DA
    Pharmacotherapy; 2007 Jun; 27(6):921-6. PubMed ID: 17542773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of bivalirudin to lepirudin and argatroban in patients with heparin-induced thrombocytopenia.
    Bain J; Meyer A
    Am J Health Syst Pharm; 2015 Sep; 72(17 Suppl 2):S104-9. PubMed ID: 26272889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of direct thrombin inhibitors in the treatment of Heparin-Induced Thrombocytopenia: a single institution experience.
    Curzio KM; Cheng-Lai A; Kheyfets V; Sinnet M; Billett HH
    J Thromb Thrombolysis; 2009 Aug; 28(2):117-23. PubMed ID: 18827975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heparin-induced thrombocytopenia in intensive care patients.
    Selleng K; Warkentin TE; Greinacher A
    Crit Care Med; 2007 Apr; 35(4):1165-76. PubMed ID: 17334253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of patients with a history of heparin-induced thrombocytopenia and anti-lepirudin antibodies with argatroban.
    Harenberg J; Jörg I; Fenyvesi T; Piazolo L
    J Thromb Thrombolysis; 2005 Feb; 19(1):65-9. PubMed ID: 15976970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Argatroban, bivalirudin, and lepirudin do not decrease clot propagation and strength as effectively as heparin-activated antithrombin in vitro.
    Nielsen VG; Steenwyk BL; Gurley WQ; Pereira SJ; Lell WA; Kirklin JK
    J Heart Lung Transplant; 2006 Jun; 25(6):653-63. PubMed ID: 16730571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Argatroban treatment of heparin-induced immune-mediated thrombocytopenia].
    Nielsen JD; Heslet L
    Ugeskr Laeger; 2009 Feb; 171(8):610-1. PubMed ID: 19284906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel fondaparinux protocol for anticoagulation therapy in adults with renal failure and suspected heparin-induced thrombocytopenia: a retrospective review of institutional protocol.
    Ghaziri D; Dehaini H; Msheik M; Bahmad M; Zorkot M; Saad GA
    BMC Pharmacol Toxicol; 2023 Jan; 24(1):2. PubMed ID: 36639796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fondaparinux: a potential new therapy for HIT.
    Kuo KH; Kovacs MJ
    Hematology; 2005 Aug; 10(4):271-5. PubMed ID: 16085538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.